38041-19-9Relevant articles and documents
Preparation method of important intermediate 4-aminotetrahydropyran
-
Paragraph 0019-0025; 0026-0032; 0033-0039; 0040-0053; 0055, (2018/12/14)
The invention discloses a preparation method of an important intermediate 4-aminotetrahydropyran. The method comprises the following steps that tetrahydro-4-pyranol is dissolved in polyethylene glycol-200, a prepared Cu-Mo/TS-1 composite is added, a mixture is heated to 60-80 DEG C, under a stirring condition, ammonium hydroxide is added into the mixture dropwise, after dropping is completed, heat-preservation stirring reaction is carried out for 5-6 h, and filtering, extraction and recrystallization are conducted to prepare the 4-aminotetrahydropyran. The preparation method is simple to operate, conditions are mild, by-products are few, the product purity is high, and the product yield is high.
Heterogeneous Catalytic Reductive Amination of Carbonyl Compounds with Ni-Al Alloy in Water as Solvent and Hydrogen Source
Sch?fer, Christian,Ni?anci, Bilal,Bere, Matthew P.,Da?tan, Arif,T?r?k, Béla
, p. 3127 - 3133 (2016/09/09)
The heterogeneous catalytic reductive amination of carbonyl compounds has been achieved by reactions of ammonium hydroxide and various amines with ketones and aldehydes. The process is based on the application of Raney type Ni-Al alloy in an aqueous medium. The reaction of the carbonyl compounds with the amine provided the corresponding Schiff bases that immediately underwent a reduction to provide primary and secondary amines as products. The controlled reaction of the Al content of the alloy with the solvent water generates hydrogen, and the in situ formed Raney Ni serves as a hydrogenation catalyst. The method is a simple and efficient way of preparing a broad variety of primary and secondary amines.
IMIDAZO [1, 2 - B] PYRIDAZINE - BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF
-
Page/Page column 29, (2013/09/26)
Imidazo[1,2-b]pyridazine-based compounds of the formula (I): are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.